Prospects not looking good yet The number of people who were tested for SARS-CoV-2 increased by 20% last week. The number of people who tested positive rose by 7%. The reproduction number also rose above 1.
RIVM collaborates at European level on the implemention of the Nutri-Score label The Netherlands, Belgium, France, Germany, Luxembourg, Spain and Switzerland are collaborating to facilitate the nutritional label NutriScore.
Care workers in nursing homes and small-scale residential facilities invited for COVID-19 vaccination starting today As of today, the ca. 269,000 care workers of nursing homes and small-scale residential facilities in the Netherlands are invited to make an appointment for a COVID-19 vaccination.
Spread of tick-borne encephalitis virus in the Netherlands Every year about 1.5 million ticks bite someone in the Netherlands, especially between March and October. Most people will not get sick of that.
Possible health risks due to exposure to chromium-6 at tROM project Tilburg Research by RIVM shows that the participants in the so-called tROM project, their supervisors and other people involved may have been exposed to chromium-6.
Plant Protection Products: new RIVM methodology calculates period in which workers must wear gloves Commissioned by the Dutch Ministry of Social Affairs and Employment (SZW), RIVM has developed a new methodology to calculate the period for which workers must wear gloves to mitigate the risk of re
Protection of Defence personnel against health risks of chromium-6 was inadequate From 1984-2006, employees of the Dutch Ministry of Defence were exposed to chromium-6 during maintenance work.
Less meat and more tap water benefits health and the environment In the Netherlands, diets with a high environmental impact contain more meat and energy.
New test has no added value in Lyme disease of the central nervous system Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.
Lyme disease costs EUR 20 million annually The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.